NCT07214766View on ClinicalTrials.gov

A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

312

Participants

Timeline

Start Date

October 17, 2025

Primary Completion Date

February 19, 2026

Study Completion Date

April 16, 2026

Conditions

Healthy Participants

Interventions

DRUG

Trastuzumab

Trastuzumab will be administered to participants as a solution for injection.

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY